Following our acquisition of Cellesce Ltd, Tanya Samazan from Instrument Business Outlook dove deep into conversation with Molecular Devices President Susan Murphy and Cellesce CEO Vicky Marsh-Durban about how their complementary expertise and technologies will accelerate organoid research.